The ACCC has asked a court to impose a $3.5 million penalty against eyewear retailer Oscar Wylee for making misleading representations about its charitable donations and affiliations, including that it would donate one pair of eyeglasses to charity for every pair purchased.
Sydney-based research foundation Brien Holden Vision Institute has filed a lawsuit alleging three senior researchers misused confidential information when they jumped ship to a rival research group and filed applications to patent seven inventions for opthalmic lenses designed to treat myopia allegedly based on that information.
The competition watchdog will not oppose Mylan NV’s proposed merger with Pfizer’s Upjohn Inc after the global pharmaceutical giants agreed to sell several off-patent brands to dispel competition concerns.
US pharmaceutical giant Merck Sharp & Dohme has taken a unit of Indian generic manufacturer Lupin to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.
German pharmaceutical giant Boehringer has partially succeeded in its opposition to several vaccine patents filed by animal health company Zoetis, used to treat pneumonia in pigs.
The State of Victoria has been hit with a class action for its allegedly negligent handling of its hotel quarantine program, which is believed to be responsible for the state’s second wave of coronavirus cases.
St. Basil’s in Victoria has become the latest aged care facility to face a class action over its allegedly negligent handling of the coronavirus pandemic.
A court has approved a $2.9 million penalty against medical booking platform HealthEngine after the company admitted to deleting and altering unfavourable reviews and misusing consumer data.
The son of a 92-year-old woman who died after she contracted COVID-19 at a Melbourne aged care home has launched a class action against the residential facility, claiming damages for stress and anxiety caused by his mother’s death.
A former QRx Pharma director’s prediction that shareholders would not receive “anything of consequence” from a class action settlement has proven true, with only a small slice of the $7 million settlement expected to go to shareholders.